Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell Transplants
- Autores: Jeffrey F. Scott, Kevin R. Brough, Konstantin V. Grigoryan, John G. Muzic, Grace Y. Kim, Rosalynn R. Z. Conic, Sheena T. Hill, Jerry D. Brewer, Christian L. Baum, Mark R. Litzow, William J. Hogan, Mrinal S. Patnaik, Shahrukh K. Hashmi, Hillard M Lazarus, Jeremy S. Bordeaux, Cheryl L. Thompson, Julia S. Lehman
- Localización: JAMA Dermatology, ISSN 2168-6068, Vol. 156, Nº. 6, 2020, págs. 631-639
- Idioma: inglés
- Enlaces
-
Resumen
Importance Allogeneic hematopoietic cell transplant (alloHCT) is known to increase the risk for keratinocyte carcinoma. The extent to which host characteristics, including pigmentary phenotype and UV radiation exposure, contribute is unknown.
Objective To identify and validate independent risk factors for keratinocyte carcinoma after alloHCT, including those associated with the transplant and the host.
Design, Setting, and Participants This retrospective cohort study analyzed a consecutive sample of alloHCT recipients from January 1, 2000, to December 31, 2014, at the Mayo Clinic, Rochester, Minnesota (n = 872) and University Hospitals Cleveland Medical Center, Cleveland, Ohio (n = 147). Participants from the Mayo Clinic were randomly allocated (2:1) into discovery (n = 581) and validation (n = 291) cohorts. Time to first keratinocyte carcinoma and information about transplant- and host-associated risk factors were extracted. A multivariate keratinocyte carcinoma risk model was created using a stepwise Cox proportional hazards regression model with P ≤ .05 for entry that incorporated all covariates that were individually statistically significant at α = 0.05 in the discovery cohort. The risk model was first internally validated using the Mayo Clinic validation cohort and then externally validated using the independent cohort of alloHCT recipients at University Hospitals Cleveland Medical Center. Data were analyzed from March 13, 2018, to June 12, 2019.
